Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31
Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ: VRDN ) from Equal-Weight to Overweight and raises the price target from $20 to $31.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.